Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

Original reporting
Published Nov 17, 2026, 11:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The clinical setback plus the analyst downgrade and price-target reduction are likely to drive near-term repricing of Aclaris’s pipeline value and development risk.

02

Market read

Traders get a concrete catalyst: a Phase 2 miss leading to expected program discontinuation, alongside a major analyst downgrade and a sharply lower price target.

03

What to watch

The article flags uncertainty around FDA acceptance of a seamless Phase 2b/3 design, which could be a swing factor for future trial timelines and risk, beyond the initial trial miss.

Relevance 8/10Novelty 6/10Timing: today, analyst downgrade and price-target cut following the trial setback

Background

Aclaris is pivoting from an atopic dermatitis Phase 2 effort after bosakitug failed to meet efficacy endpoints, while emphasizing ATI-052 for eosinophilic esophagitis.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Wedbush downgraded Aclaris Therapeutics to Neutral and cut its price target after the Phase 2 ADMIRATION trial for bosakitug missed efficacy endpoints.

Expected impact

Likely downside pressure as the market reprices the probability-weighted pipeline after the trial miss and development reprioritization.

Evidence & confidence

The article cites a specific Phase 2 failure, a stated expectation to discontinue atopic dermatitis development, and a concrete analyst downgrade with a large price-target cut.

Market effects

Reinforces risk-off sentiment for immunology/dermatology biotech programs where Phase 2 misses can quickly reset pipeline expectations.

Limited, primarily affects US small/mid-cap biotech sentiment rather than broad indices.

Low, as the catalyst is company-specific clinical-trial and analyst-reaction news.

Counterpoint

ATI-052 reprioritization to eosinophilic esophagitis could still offer a credible path if upcoming regulatory discussions and interim data support the design.

Key entities

  • Aclaris Therapeutics

    Subject of the article; downgraded after Phase 2 ADMIRATION trial failure and development reprioritization.

  • bosakitug

    Phase 2 ADMIRATION candidate for atopic dermatitis that failed primary and secondary efficacy endpoints.

  • ATI-052

    Reprioritized candidate for eosinophilic esophagitis; Wedbush notes potential regulatory and interim-data sensitivity.

  • FDA

    Wedbush questions whether the proposed seamless Phase 2b/3 design will be accepted.

Related articles

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.

$ACRSMed

Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.